Breaking Down Nipro Corporation Financial Health: Key Insights for Investors

Curious how Nipro Corporation's latest filings reshape the investment picture? The company reported a fiscal-year revenue rise of 9.85% to ¥644.59 billion (FY Mar 31, 2025) with TTM revenue at ¥649.95 billion (+6.04% YoY) while quarterly sales for Q3 (ending Sep 30, 2025) slipped slightly to ¥158.16 billion (-0.92%); market capitalization sits at ¥236.81 billion (+5.22% year), and revenue per employee is about ¥16.59 million across ~39,168 staff - yet profitability shows strain with net income down to ¥5.11 billion (‑53.97% YoY), EPS (TTM) ¥59.16 and a P/E of 24.54 (forward P/E 17.24); leverage is notable with a debt-to-equity ratio of 2.16 (total debt ¥634.47 billion vs. equity ¥238.21 billion), enterprise value ¥832.25 billion, current and quick ratios at 1.50 and 0.66 respectively, operating cash flow (TTM) ¥68.46 billion but negative free cash flow of -¥8.15 billion, interest coverage 3.31, P/S 0.37 and P/B 0.81 - and against this mixed financial backdrop, growth levers such as expansion in the Americas, Europe and Asia, sterile medical solutions, new detection kits (including Mpox), and FDA IDE approval for the INSYTE US pivotal trial point to where upside could emerge; read on to dissect these metrics, valuation signals and risks in depth

Nipro Corporation (8086.T) Revenue Analysis

• Annual revenue (FY end Mar 31, 2025): ¥644.59 billion (+9.85% YoY from ¥586.79 billion)
• Quarter revenue (Q2 ended Sep 30, 2025): ¥158.16 billion (-0.92% YoY)
• Trailing twelve months (TTM) revenue: ¥649.95 billion (+6.04% YoY)
• Price-to-sales (P/S) ratio: 0.37
• Market capitalization (Dec 9, 2025): ¥236.81 billion (+5.22% over 1 year)
• Employees: ~39,168 - Revenue per employee: ≈ ¥16.59 million

• Interpretation: The FY growth rate (9.85%) and positive TTM trend (+6.04%) indicate recovery/expansion versus the prior year, while the slight quarterly dip (-0.92%) suggests short-term variability that investors should monitor alongside margin and segment disclosure.
• Valuation context: A P/S of 0.37 and market cap of ¥236.81 billion imply modest market valuation relative to sales; combine with profitability metrics to assess investment attractiveness.
• Operational efficiency: Revenue per employee (~¥16.59M) provides a baseline for productivity comparisons within the industry.

Nipro Corporation (8086.T) Profitability Metrics

Nipro Corporation reported a net income of ¥5.11 billion for the fiscal year ending March 31, 2025, down 53.97% from ¥11.11 billion in the prior year. The company's profitability profile shows constrained margins and modest returns relative to equity.

• Net income (FY end Mar 31, 2025): ¥5.11 billion (-53.97% YoY)
• Operating margin: 4.38%
• Net profit margin: 1.68%
• Return on equity (ROE): 4.52%
• Earnings per share (TTM): ¥59.16
• Price-to-earnings (P/E) ratio: 24.54
• Dividend yield: 1.95% (ex-dividend date: March 30, 2026)

Key observations for investors:

• Sharp YoY decline in net income suggests near-term profitability pressures or one-off items affecting FY2025 results.
• Operating margin of 4.38% indicates limited buffer between revenue and operating costs; potential sensitivity to cost inflation or revenue fluctuations.
• Net profit margin at 1.68% and ROE of 4.52% reflect modest conversion of sales into shareholder returns.
• P/E of 24.54 on EPS ¥59.16 positions the stock at a multiple that implies investor expectations of recovery or growth; evaluate relative to peers and sector averages.
• Dividend yield 1.95% with upcoming ex-dividend date (Mar 30, 2026) provides some income component but is not high relative to typical income-focused names.

For context on corporate direction and strategic priorities that may influence future profitability, see: Mission Statement, Vision, & Core Values (2026) of Nipro Corporation.

Nipro Corporation (8086.T) - Debt vs. Equity Structure

• Debt-to-Equity Ratio: 2.16 - Nipro carries ¥2.16 of debt for every ¥1 of equity, indicating higher reliance on borrowed capital.
• Total Debt: ¥634.47 billion - the aggregate interest-bearing obligations on the balance sheet.
• Stockholders' Equity: ¥238.21 billion - the residual claim of shareholders after liabilities.
• Current Ratio: 1.50 - current assets are 1.5× current liabilities, suggesting adequate short-term coverage overall.
• Quick Ratio: 0.66 - excluding inventory, liquid assets cover only 66% of current liabilities, signaling potential near-term liquidity pressure without inventory conversion.
• Interest Coverage Ratio: 3.31 - operating earnings cover interest expense roughly 3.3 times, a moderate cushion but below conservative safety margins.
• Enterprise Value: ¥832.25 billion - market+debt view of firm value reflecting both equity and debt claims.

• Leverage sensitivity: With a 2.16 debt-to-equity ratio, earnings volatility or rising rates could quickly pressure cash flows and leverage metrics.
• Liquidity profile: The gap between the current ratio (1.50) and quick ratio (0.66) highlights dependence on inventory turnover to meet short-term obligations.
• Debt-servicing capacity: An interest coverage of 3.31 provides some buffer, but margin for unexpected shocks or cyclical downturns is limited compared with higher-coverage peers.
• Valuation context: Enterprise value of ¥832.25 billion places market valuation in the context of the company's debt load-useful for takeover, leverage-adjusted valuation, or comparables analysis.

Nipro Corporation (8086.T) - Liquidity and Solvency

Nipro Corporation (8086.T) presents a mixed liquidity and solvency profile: solid operational cash generation but negative free cash flow and moderate short-term liquidity cushion. Key figures below quantify these dynamics and their implications for investors.

• Operating cash flow (TTM): ¥68.46 billion - healthy cash generation from core operations.
• Free cash flow (TTM): -¥8.15 billion - indicates capital expenditures exceed operating cash inflows.
• Cash & cash equivalents: ¥106.10 billion - a sizeable liquidity buffer.
• Quick ratio: 0.66 - potential difficulty covering short-term liabilities without relying on inventory sales.
• Current ratio: 1.50 - adequate short-term financial health when inventory is included.
• Interest coverage ratio: 3.31 - able to meet interest expenses but with limited margin for stress.

Practical considerations for investors:

• Monitor capex plans and timing - persistent negative FCF could pressure liquidity unless offset by asset sales, refinancing, or sustained operating cash growth.
• Evaluate working capital trends, especially inventory levels, since a quick ratio below 1 implies reliance on inventory turnover to meet near-term liabilities.
• Track debt maturities and interest costs given an interest coverage ratio of 3.31; rising rates or lower margins would compress coverage quickly.
• Cash reserves of ¥106.10 billion provide a near-term buffer, but stewardship of that cash relative to investment and debt obligations is critical.

For broader context on company strategy and how Nipro generates revenue and value, see: Nipro Corporation: History, Ownership, Mission, How It Works & Makes Money

Nipro Corporation (8086.T) - Valuation Analysis

Nipro Corporation (8086.T) presents a mixed valuation profile: solid revenue growth with several valuation multiples suggesting relative undervaluation versus peers, while earnings multiples reflect market expectations for future profitability improvement.

• TTM revenue: ¥649.95 billion (YoY growth: 6.04%)
• Market capitalization (as of 2025-12-09): ¥236.81 billion (1‑yr change: +5.22%)
• Enterprise value (EV): ¥832.25 billion
• Price-to-Sales (P/S): 0.37
• Price-to-Book (P/B): 0.81
• Price-to-Earnings (P/E): 24.54; Forward P/E: 17.24

Key valuation implications:

• The low P/S (0.37) and sub-1 P/B (0.81) point toward relative undervaluation on a balance-sheet and revenue basis, which may attract value-oriented investors.
• The gap between TTM P/E (24.54) and forward P/E (17.24) signals expected earnings acceleration or margin recovery reflected in analyst estimates and market pricing.
• Enterprise value (¥832.25 billion) vs. market cap (¥236.81 billion) indicates material leverage or non-equity claims; EV/Revenue and EV/EBITDA should be examined for capital-structure-adjusted comparisons.

For investor-focused context and shareholder composition insights, see: Exploring Nipro Corporation Investor Profile: Who's Buying and Why?

Nipro Corporation (8086.T) - Risk Factors

Nipro Corporation (8086.T) faces several measurable financial risks that investors should weigh alongside strategic and market considerations.

• Debt-to-Equity Ratio: 2.16 - indicates a higher reliance on debt financing and greater leverage risk in downturns.
• Free Cash Flow: -¥8.15 billion - capital expenditures exceed operating cash flow, reducing financial flexibility.
• Quick Ratio: 0.66 - potential difficulty meeting short-term obligations without liquidating inventory.
• Net Income Change: -53.97% YoY - a substantial decline in profitability compared with the prior year.
• Operating Margin: 4.38% and Net Profit Margin: 1.68% - relatively low margins that highlight cost-management pressure.
• Interest Coverage Ratio: 3.31 - positive but modest cushion for interest payments; may be thin in capital-intensive or cyclical stress.

For broader context on the company's background and how it generates revenue, see: Nipro Corporation: History, Ownership, Mission, How It Works & Makes Money

Nipro Corporation (8086.T) - Growth Opportunities

• Geographic expansion: ramping capacity in the Americas and Europe alongside established Asian operations to diversify revenue and reduce currency/market concentration risks.
• Vertical integration: in‑house glass packaging, sterile filling and logistics that lower COGS and shorten time‑to‑market for specialized products (dialysis consumables, injectable delivery systems).
• Clinical & regulatory catalysts: the FDA IDE approval for the INSYTE US Pivotal Trial assessing the nOCT Imaging System during brain aneurysm treatment opens a high‑value device pathway in neurointervention.
• Diagnostic product development: new detection kits (e.g., Mpox) demonstrate agility to address emerging infectious disease needs and bolster recurring reagent sales.
• Manufacturing investments: expansion and automation investments aimed at increasing throughput for sterile injectables and dialysis components to capture market share from constrained suppliers.
• Competitive moat: decades of regulatory compliance and glass packaging expertise that sustain high entry barriers in sterile pharmaceutical packaging and dialysis supply segments.

• Geographic revenue mix (approx.): Asia 45%, Americas 30%, Europe 25% - showing meaningful runway for incremental growth from further penetration in Western markets.
• Segment exposure: dialysis consumables, injectable delivery systems, pharmaceutical packaging, diagnostics and medical devices - each with differing margin profiles; focus on sterile injectables and devices tends to drive higher ASPs and margins.

• Capacity additions and near‑term capex can lift annual revenue growth by mid‑single digits to high‑single digits if utilization rises and new product ramps succeed.
• Successful commercialisation of the nOCT system via the INSYTE pivotal study could create a new high‑margin device revenue stream and increase device segment profitability over multiple years.
• Expansion of diagnostic kits (e.g., Mpox and future assays) supports recurring reagent revenue with strong gross margins and rapid scalability through existing distribution channels.
• Operational leverage from vertical integration can improve adjusted operating margin by 100-200 bps over time as scale and automation reduce per‑unit costs.

• Key KPIs to watch: utilization rates of new sterile lines, regulatory approvals and trial milestones (INSYTE pivotal trial enrollment and endpoints), time to commercial launch for diagnostic kits, and geographic revenue mix shifts.
• Balance sheet metrics: capex trajectory vs. free cash flow, and any M&A or JV activity to accelerate market entry in the Americas/Europe.